Tiotropium

Publication Details

Estimated reading time: 1 minute

CASRN: 136310-93-5

image 135087660 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

Although no published data exist on the use of tiotropium, its use produces negligible maternal serum levels and any drug in breastmilk would not be absorbed by the infant. The risk to the breastfed infant of maternal tiotropium inhalation is small. International guidelines agree that breastfeeding can continue during tiotropium therapy.[1,2]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Aclidinium, Umeclidinium

References

1.
Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J 2020;55:1901208 [PubMed: 31699837]
2.
Bendien SA, de Kruif MD, Feitsma H, et al. Summary of the Dutch Multidisciplinary Practice Guideline on Asthma and Pregnancy. J Allergy Clin Immunol Pract 2024;12:1751-62 [PubMed: 38513758]

Substance Identification

Substance Name

Tiotropium

CAS Registry Number

136310-93-5

Drug Class

Breast Feeding

Lactation

Milk, Human

Anti-Asthmatic Agents

Bronchodilator Agents

Muscarinic Antagonists

Parasympatholytics

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.